MedTrace Logo

Cardiac Transplant Metabolomics With and Without Rejection

NCT05772442 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2024-07-23

No results posted yet for this study

Summary

Patient who received a heart transplant may develop organ rejection. Currently, an invasive biopsy of the heart needs to be performed to diagnose rejection. The purpose of this research study is to identify novel metabolic biomarkers that can be developed into a blood test that can identify signs of rejection without doing a heart biopsy.

Conditions

  • Heart Transplant Rejection

Interventions

DIAGNOSTIC_TEST

Extra blood samples (5-10 mL) drawn

Extra blood samples will be sent for metabolomics analysis.

Sponsors & Collaborators

  • Canadian Cardiovascular Society

    collaborator OTHER

  • Bayer

    collaborator INDUSTRY

  • University of Alberta

    collaborator OTHER

  • Queen's University

    collaborator OTHER

  • Western University, Canada

    lead OTHER

Principal Investigators

  • Stuart Smith, MD · Western University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-07-31
Primary Completion
2025-10-31
Completion
2026-04-30

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05772442 on ClinicalTrials.gov